Changing the landscape for type 1 diabetes: the first step to prevention

@article{Dayan2019ChangingTL,
  title={Changing the landscape for type 1 diabetes: the first step to prevention},
  author={Colin M. Dayan and Mariam P. Korah and Danijela Tatovi{\'c} and Brian N. Bundy and Kevan C. Herold},
  journal={The Lancet},
  year={2019},
  volume={394},
  pages={1286-1296}
}
View on Elsevier
doi.org
32 Citations
Background Citations
10

32 Citations

Immunotherapy for type 1 diabetes.
TLDR
A consensus on how to identify individuals who may benefit from immunotherapy to prevent disease onset is needed, and the development of optimal strategies for preventing and delaying progression of type 1 diabetes, and monitoring the response to immunointervention are needed.
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes
TLDR
The history and current status of immunotherapy for T1D is outlined, and the activities of Diabetes TrialNet, a National Institutes of Health consortium launched in 2004, are focused on.
Type 1 diabetes mellitus: much progress, many opportunities.
  • A. Powers
  • Medicine, Biology
    The Journal of clinical investigation
  • 2021
TLDR
It is now clear that there is considerable heterogeneity in T1D with regards to genetics, pathology, response to immune-based therapies, clinical course, and susceptibility to diabetes-related complications.
Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes
  • D. Tatović, C. Dayan
  • Medicine, Biology
    Diabetic medicine : a journal of the British Diabetic Association
  • 2021
TLDR
Type 1 diabetes scientific community has a challenging task ahead—to fundamentally change the management of this devastating disease by using low‐risk immunotherapy to preserve endogenous beta‐cell function and make metabolic control substantially easier.
CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes
TLDR
The pharmacokinetic parameters and pharmacodynamic markers of abatacept are shown in vivo and in clinical trials, guiding dosage regimen recommendations for future investigational studies and expert opinion Immunomodulation is one of the promising strategies for decelerating the progression of beta-cell destruction after the onset of T1D.
Pathogenesis of Type 1 Diabetes: Established Facts and New Insights
TLDR
The interplay between genetic predisposition and other non-genetic factors, such as viral infections, diet, and gut biome, which all potentially contribute to the aetiology of T1D are highlighted.
Type 1 diabetes mellitus and its oral tolerance therapy
TLDR
A current overview of oral tolerance therapy for T1DM conducted in both animal models and clinical trials is given, acting as an antigen-specific immunotherapy for type 1 diabetes mellitus.
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
TLDR
The findings that apolipoprotein CIII (apoCIII) is increased in T1D and that in vitro studies revealed that healthy β-cells exposed to apoCIII became apoptotic are summarized to highlight the need for exploring this field as the authors still are only seeing the top of the iceberg.
Gastrointestinal Microbiota and Type 1 Diabetes Mellitus: The State of Art
TLDR
Available data on the associations between gut microbiota and T1DM in both experimental animals and humans are summarized and future perspectives in this novel and exciting area of research are discussed.
Advanced Approaches in Immunotherapy for the Treatment of Type 1 Diabetes Mellitus
TLDR
An ever-evolving field of immunology has shifted the paradigm of how T1DM is understood, and the repurposing of T-cellbased biotechnology has the potential to change the way that it is treated.
...
...

References

SHOWING 1-10 OF 101 REFERENCES
The challenge of modulating β-cell autoimmunity in type 1 diabetes.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
TLDR
Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants and among the participants who were Hla-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody- negative, fewer participants in the teplizuab group than in the placebo group had diabetes diagnosed.
Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial
TLDR
Among autoantibody-positive relatives of patients with type 1 diabetes, oral insulin at a dose of 7.5 mg/d, compared with placebo, did not delay or prevent the development of type 2 diabetes over 2.7 years.
Primary prevention of beta-cell autoimmunity and type 1 diabetes – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
TLDR
Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes, as suggested by the results of a phase 1 study.
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
TLDR
Treatment with hOKT3gamma1(Ala-Ala) mitigates the deterioration in insulin production and improves metabolic control during the first year of type 1 diabetes mellitus in the majority of patients.
The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.
TLDR
It is concluded that in this subgroup of diabetes-prone individuals at very high risk and with an assumed rapid disease progression, nicotinamide treatment did not cause a major decrease or delay of diabetes development.
Genetics, pathogenesis and clinical interventions in type 1 diabetes
TLDR
Current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies are described.
Primary Dietary Intervention Study to Reduce the Risk of Islet Autoimmunity in Children at Increased Risk for Type 1 Diabetes
TLDR
Delaying gluten exposure until the age of 12 months is safe but does not substantially reduce the risk for islet autoimmunity in genetically at-risk children.
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
TLDR
These findings suggest there is reduced decline in C-peptide and persistent immunological responses up to 7 years after diagnosis of diabetes in individuals who respond to teplizumab.
...
...